Wolverine legal status for BPC-157 TB-500

Wolverine legal status involves the prescriber and the ingredients

Wolverine legal status concerns pharmacy permission to prepare medicine containing BPC-157 or TB-500. People asked FDA, the agency overseeing medicines, to consider allowing these ingredients. The applicants later pulled back their requests for those ingredients. Pulling back a request gives no permission to compound the ingredient. July 23-24, 2026: a committee advising FDA discussed possible additions to the pharmacy ingredient list ^[14]. Discussion didn't grant permission.

At mypromise.com, Promise Peptides prescribes Wolverine, a BPC-157 and TB-500 blend whose medication requires a prescription. Each case goes to a licensed U.S. clinician, and some patients are declined; the service sees only U.S. patients, with offerings restricted by state and by the treatment considered. The compounded medicine has no FDA approval, and the prescription leaves the compounder responsible for the ingredient rules.

FDA previously put the two ingredients into Category 2, its group for serious safety concerns ^[12]. FDA now lists both nominations as withdrawn, rather than in Category 2 ^[12]. The warnings remain on that page. Category 2 meant a pharmacy using the ingredient could face action from FDA. Withdrawing the requests did not resolve the safety concerns or put either ingredient in Category 1.

The July 2026 meeting addressed whether to add ingredients to the pharmacy's allowed list ^[14]. FDA hasn't published the committee's voting results. A discussion agenda cannot supply that missing decision. A clinician’s prescribing decision and the compounder’s legal duties remain separate. This page explains the rules in general; no professional here assesses your care or your legal circumstances. Neither substance is supplied here.

Withdrawn nominations

On FDA’s page current as of April 22, 2026, BPC-157 and thymosin beta-4 fragment (LKKTETQ), also known as TB-500, appear in the table of bulk drug substances whose nominations were withdrawn. They previously appeared in Category 2. The safety rationales remain attached to the withdrawn entries.

FDA identifies concerns about immune reactions, impurities and characterization of these substances. Withdrawal supplies neither drug approval nor Category 1 placement. An entry's location says little about patient safety.

503A and 503B preparation

The FDA compounding framework distinguishes section 503A, generally covering patient-specific preparation by a licensed pharmacy or physician, from section 503B, covering registered outsourcing facilities. A bulk ingredient needs an applicable legal basis. Relevant routes include a recognized drug standard, a component of an approved drug, or inclusion on the applicable bulks list.

A prescription addresses a particular patient's care; the compounder must separately determine whether the proposed preparation meets the requirements. The nominations being withdrawn authorizes no compounding. Neither BPC-157 nor TB-500 has FDA drug approval, and compounded Wolverine is not FDA-approved.

July committee discussion

FDA's July 23–24, 2026 committee calendar listed BPC-157 and TB-500 for consideration for the 503A Bulks List. The existing record describes staff advice against adding either ingredient and, as checked in September 2026, no published official account of the votes. An agenda records a discussion topic; it cannot supply a final permission.

I would treat any claim that the committee cleared Wolverine with particular care. It needs a published decision supporting exactly that claim. The record preserved here supplies no such approval.

WADA prohibition

Both ingredients are prohibited under World Anti-Doping Agency rules. BPC-157 falls under non-approved-substance rules; TB-500 and thymosin beta-4 fall under prohibited peptide and growth-factor categories. The prohibition applies in and out of competition. The sports-medicine review places these substances within the broader problem of unapproved peptide use in sport.

A medical-sounding name cannot answer a sporting eligibility question. Nor does a promising animal finding decide either the pharmacy requirements or the risks of using the blend.